Impact of Online Patient Feedback (OQ) to Therapist

Status Completed

Clinical Trial Summary

Dropout represents one of the largest problems in substance abuse treatment. International and Nordic research show that only 20 - 40 % of substance abusers complete treatment as intended. At the same time, one of the most consistent factors of favourable post-treatment outcome is treatment completion. In spite of the serious and continuous challenge dropout represents the phenomena is not well understood and there is a need to explore more of the factors that influence dropout and how it can be counteracted. As also stated: "…effective methods for reducing the problem of dropouts from treatment is one more area in need of further research" (NOU 2003:4, s 77). For the general field of mental health one of the most important innovations involves providing therapists with patient feedback about their progress. The most well-established and widely researched feedback system is the Outcome Questionnaire (OQ-45.2). The system has been shown to improve treatment outcomes, including reduced treatment dropout and length of treatment, but the system is yet to be utilized with a substance abusing patient group. The aim of the present study is to examine the usefulness of OQ-45.2 with substance abusing patients.

Clinical Trial Description

Hypotheses and research questions 1. The OQ-45.2 feedback will be effective in identifying patients at risk of dropout of substance abuse treatment. 1a. The condition were feedback is withheld from the therapist, will correctly identify patients who will dropout. Research Question: Is there variation in the accuracy of dropout prediction as a function of age, gender differences or type of substance abuse? 2. The OQ-45.2 feedback will be effective in reducing dropout in outpatient substance abuse treatment. 2a. The feedback condition will result in less dropout than the no-feedback condition. Research Question: Is there a variation in the OQ-45.2 preventive dropout effect due to age, gender or type of substance abuse? 3. The OQ-45.2 feedback will shorten length of inpatient substance abuse treatment. 3a. The feedback condition will identify patients who are ready to terminate therapy. Research Question: Is there variation in identification of patients ready to terminate as a function of age, gender differences or type of substance abuse? ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01891045
Study type	Interventional
Source	Oslo University Hospital
Contact
Status	Completed
Phase	N/A
Start date	July 1, 2011
Completion date	January 3, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02224508` - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks	N/A
Completed	`NCT02282306` - Phone Interview to Prevent Recurring Opioid Overdoses	N/A
Completed	`NCT02375516` - Preventing Drug Abuse Among Hispanic Adolescents	N/A
Withdrawn	`NCT01275391` - cSBIRT to Reduce Teen Tobacco, Alcohol and Drug Use	Phase 1/Phase 2
Completed	`NCT01442753` - Family-Skills Training to Prevent Tobacco and Other Substance Use in Latino Youth	N/A
Completed	`NCT00907309` - Dental and Medical Office iMET to Reduce Teen Tobacco, Alcohol, and Drug Use	Phase 1/Phase 2
Completed	`NCT02228044` - Alcohol, Suicide and HIV Prevention for Teens in Mental Health Treatment	N/A
Withdrawn	`NCT01427465` - Brief Integrative Alcohol Interventions for Adolescents	N/A
Completed	`NCT00350909` - Brief Intervention for Drug Abusing Adolescents	Phase 2
Completed	`NCT00148031` - Improving Hepatitis C Treatment in Injection Drug Users	Phase 4
Completed	`NCT00383838` - Self-Selected Brief Alcohol Intervention for Adolescents	N/A
Completed	`NCT00451854` - Student Athlete Testing Using Random Notification	N/A
Completed	`NCT00722644` - Cognitive Behavioral Stress Management for HIV+ Drug Abusers	Phase 1
Completed	`NCT01036711` - Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI
Terminated	`NCT02741076` - Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain	Phase 4
Completed	`NCT01035723` - Effect of Functional Genetic Polymorphisms on Brain Morphology and Function
Completed	`NCT06044363` - Satir Model for Self-esteem, Mental Health, and Family Function Among Individuals With Substance Use Disorders	N/A
Recruiting	`NCT05037487` - Evaluation of Smoked THC and CBD in Men and Women	Phase 1
Recruiting	`NCT04725266` - A Family-based Intervention for Drug-abusing Adults in Hong Kong	N/A
Completed	`NCT03678051` - CBT4CBT for Women in Residential Treatment for Substance Use Disorders	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.